Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study were to prospectively record and analyze birth defects
and spontaneous fetal losses in women with multiple sclerosis (MS) exposed to Avonex within
approximately 1 week of conception or during the first trimester of pregnancy, where the
outcome of the pregnancy was unknown prospectively and to prospectively record and analyze
pregnancy outcomes in an exploratory fashion of women with MS who stopped therapy, but who
may have been exposed to Avonex with approximately 1 week of conception or during the first
trimester of pregnancy.